Covered recipient · General Payments record
LASIKA C SENEVIRATNE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$12,970.67
188 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,830.00 | 3 |
| Food and Beverage | $3,854.81 | 178 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,350.00 | 1 |
| Travel and Lodging | $925.01 | 5 |
| Education | $10.85 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LASIKA C SENEVIRATNE
NPI 1437268174 · CMS profile ID 156415
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
188 matching records · $12,970.67 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 188.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.64 | 06/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944185489 | CMS |
| Amgen Inc. | $17.45 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939826015 | CMS |
| GlaxoSmithKline, LLC. | $14.66 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944847965 | CMS |
| Coherus Biosciences Inc. | $20.06 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956562411 | CMS |
| Global Blood Therapeutics, Inc. | $20.45 | 06/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942702443 | CMS |
| GENZYME CORPORATION | $31.00 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938914787 | CMS |
| Genentech USA, Inc. | $31.00 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950772969 | CMS |
| GENZYME CORPORATION | $16.34 | 06/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938914785 | CMS |
| ARRAY BIOPHARMA INC | $23.95 | 06/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949182649 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.30 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948113 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.60 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948115 | CMS |
| Karyopharm Therapeutics Inc. | $33.31 | 05/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946522031 | CMS |
| PFIZER INC. | $13.08 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949142757 | CMS |
| TOLMAR Pharmaceuticals, Inc. | $16.40 | 05/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954452481 | CMS |
| PharmaEssentia USA Corporation | $18.53 | 05/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941274635 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.77 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955817961 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.64 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915610993 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.96 | 05/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915885871 | CMS |
| MorphoSys, US Inc. | $20.26 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962537769 | CMS |
| Amgen Inc. | $24.85 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939171063 | CMS |
| Genentech USA, Inc. | $22.71 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950773863 | CMS |
| GENZYME CORPORATION | $11.98 | 05/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938914771 | CMS |
| Kite Pharma, Inc. | $21.72 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920058451 | CMS |
| Genentech USA, Inc. | $21.38 | 05/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950766923 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.13 | 04/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929813477 | CMS |
| Incyte Corporation | $26.44 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943019679 | CMS |
| G1 Therapeutics, Inc. | $21.48 | 04/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954038459 | CMS |
| Gilead Sciences, Inc. | $22.30 | 04/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929579687 | CMS |
| Celgene Corporation | $24.18 | 04/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948081 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.29 | 04/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915439519 | CMS |
| Celgene Corporation | $24.80 | 04/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948101 | CMS |
| Incyte Corporation | $24.80 | 04/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943019675 | CMS |
| EISAI INC. | $22.31 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908056259 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.48 | 04/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915112451 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.85 | 04/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915174645 | CMS |
| Genentech USA, Inc. | $24.13 | 04/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950782877 | CMS |
| Kyowa Kirin, Inc. | $18.03 | 04/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 905052429 | CMS |
| Seagen Inc. | $18.36 | 04/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904115657 | CMS |
| EISAI INC. | $16.92 | 04/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908056263 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1.36 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948087 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.44 | 04/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948089 | CMS |
| Celgene Corporation | $23.80 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932948073 | CMS |
| Merck Sharp & Dohme LLC | $10.85 | 03/30/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944060451 | CMS |
| Janssen Biotech, Inc. | $18.95 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885557227 | CMS |
| ARRAY BIOPHARMA INC | $16.23 | 03/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949098709 | CMS |
| PFIZER INC. | $14.16 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949087907 | CMS |
| GENZYME CORPORATION | $19.99 | 03/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938914759 | CMS |
| Novartis Pharmaceuticals Corporation | $2,025.00 | 03/23/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894347203 | CMS |
| Gilead Sciences, Inc. | $17.22 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929579685 | CMS |
| Genentech USA, Inc. | $24.49 | 03/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950783943 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,972,622.10 | 108 |
| PY2024 | Principal investigator | $705,990.50 | 100 |
| PY2023 | Principal investigator | $1,487,371.44 | 252 |
| PY2022 | Principal investigator | $1,410,490.16 | 167 |
| PY2021 | Principal investigator | $866,333.17 | 24 |
| PY2020 | Principal investigator | $1,330,477.56 | 14 |
| PY2019 | Principal investigator | $248,935.94 | 33 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
108 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 12/30/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337084 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $554.93 | 12/29/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | ALI-1201 | No dispute reported | 06/30/2026 | 1251753400 |
| Principal investigator 1 | Genentech, Inc. | $3,182.00 | 12/22/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211621371 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $11,737.82 | 12/17/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745024 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $210,000.00 | 12/11/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | Patient Journey, Treatment Patterns, and Clinical Outcomes of Women Diagnosed With HR+/HER2 Early-Stage Breast Cancer | No dispute reported | 06/30/2026 | 1190307471 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,576.00 | 12/09/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190334464 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 12/05/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745026 |
| Principal investigator 1 | Genentech, Inc. | $122.00 | 12/01/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211621367 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $50,909.80 | 11/26/2025 | Non-covered Recipient Entity Los Angeles Hematology Oncology Medical Group | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1235996165 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 11/14/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745022 |
| Principal investigator 1 | BeOne Medicines Ltd. | $62,880.00 | 11/12/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330167 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 11/12/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330169 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,740.00 | 11/12/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190334468 |
| Principal investigator 1 | Incyte Corporation | $11,019.98 | 11/10/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240547947 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,131.25 | 11/07/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192103263 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211621318 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,539.10 | 10/17/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY | No dispute reported | 06/30/2026 | 1185544459 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,780.00 | 10/15/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | ALI-1201 | No dispute reported | 06/30/2026 | 1251753402 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $34,007.85 | 10/15/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | ALI-1201 | No dispute reported | 06/30/2026 | 1251753406 |
| Principal investigator 1 | Genentech, Inc. | $7,891.00 | 10/14/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211621359 |
| Principal investigator 1 | Genentech, Inc. | $10,187.00 | 10/08/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211621337 |
| Principal investigator 1 | PFIZER INC. | $22,750.00 | 10/08/2025 | Non-covered Recipient Entity Los Angeles Hematology Oncology Medical Group | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK46 INHIBITORBASED THERAPY | No dispute reported | 06/30/2026 | 1228740912 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/01/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745018 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 10/01/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745020 |
| Principal investigator 1 | BeOne Medicines Ltd. | $10,610.00 | 09/30/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190334458 |
| Principal investigator 1 | BeOne Medicines Ltd. | $62,880.00 | 09/29/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336876 |
| Principal investigator 1 | Genentech, Inc. | $23,320.00 | 09/24/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients | No dispute reported | 06/30/2026 | 1211621363 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $13,800.00 | 09/19/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745016 |
| Principal investigator 1 | Genentech, Inc. | $11,469.00 | 09/17/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211621334 |
| Principal investigator 1 | PFIZER INC. | $24,270.00 | 09/09/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MED | A PHASE 1B2 OPENLABEL MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER | No dispute reported | 06/30/2026 | 1228757601 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $750.00 | 09/05/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745014 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 09/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330145 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,879.04 | 09/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330147 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,000.00 | 08/29/2025 | Non-covered Recipient Entity Los Angeles Cancer Research | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1235996171 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $43,746.10 | 08/27/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544461 |
| Principal investigator 1 | BeOne Medicines Ltd. | $23,351.00 | 08/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190334450 |
| Principal investigator 1 | Genentech, Inc. | $5,985.00 | 08/15/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211621354 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $4,410.45 | 08/15/2025 | Non-covered Recipient Entity LOS ANGELES CANCER NETWORK | ALI-1201 | No dispute reported | 06/30/2026 | 1251753404 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,000.00 | 08/08/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745010 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 08/08/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233745012 |
| Principal investigator 1 | BeOne Medicines Ltd. | $62,880.00 | 08/05/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336941 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,879.04 | 08/05/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336945 |
| Principal investigator 1 | BeOne Medicines Ltd. | $37,564.99 | 07/22/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190334454 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,600.00 | 07/15/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328053 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,758.08 | 06/27/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336992 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,395.20 | 06/27/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336997 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 06/20/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330149 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,104.10 | 06/12/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF TAK-573 AS A SINGLE AGENT IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1223281162 |
| Principal investigator 1 | Genentech, Inc. | $12,575.00 | 06/11/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211621321 |
| Principal investigator 1 | BeOne Medicines Ltd. | $62,880.00 | 06/10/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337053 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,879.04 | 06/10/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337058 |
| Principal investigator 1 | Genentech, Inc. | $4,078.00 | 05/23/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211621341 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 05/21/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323502 |
| Principal investigator 1 | BeiGene, Ltd. | $17,188.99 | 05/20/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320424 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 05/08/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323564 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 05/08/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323566 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 05/08/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323568 |
| Principal investigator 1 | BeiGene, Ltd. | $12,467.00 | 04/29/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320902 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.62 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192103244 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.62 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192103252 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,469.75 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192103258 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.62 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192104651 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.62 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192104657 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.62 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192104663 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,298.25 | 04/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192104669 |
| Principal investigator 1 | BeiGene, Ltd. | $62,880.00 | 04/25/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325232 |
| Principal investigator 1 | BeiGene, Ltd. | $17,225.44 | 04/22/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321862 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16.36 | 04/21/2025 | Non-covered Recipient Entity Los Angeles Hematology Oncology | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1235996169 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,618.47 | 04/16/2025 | Non-covered Recipient Entity SOUTHERN CA ONCOLOGY RESEARCH ALLIANCE | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190308354 |
| Principal investigator 1 | Genentech, Inc. | $3,873.00 | 04/15/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211621349 |
| Principal investigator 1 | BeiGene, Ltd. | $17,973.99 | 04/08/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320422 |
| Principal investigator 1 | AstraZeneca UK Limited | $119,808.30 | 04/02/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185544455 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 03/31/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321892 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 03/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321964 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 03/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321966 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 03/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321968 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 03/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321970 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 03/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321972 |
| Principal investigator 1 | BeiGene, Ltd. | $11,302.00 | 03/25/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320418 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 03/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321912 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 03/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321914 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 03/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325258 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 03/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325260 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 03/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325262 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 03/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325274 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 03/03/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325276 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $33,083.22 | 02/28/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185544463 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,046.14 | 02/25/2025 | Non-covered Recipient Entity Los Angeles Hematology Oncology | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1235996167 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 02/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321934 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 02/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321936 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 02/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321938 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 02/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323530 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 02/19/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323532 |
| Principal investigator 1 | Genentech, Inc. | $1,800.00 | 02/19/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211621325 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 02/11/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322024 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 02/11/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322026 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 02/11/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322028 |
| Principal investigator 1 | Genentech, Inc. | $5,028.00 | 02/05/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211621311 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $34,147.59 | 01/29/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185544467 |
| Principal investigator 1 | BeiGene, Ltd. | $4,774.00 | 01/28/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190320420 |
| Principal investigator 1 | Celgene Corporation | $164,778.40 | 01/27/2025 | Non-covered Recipient Entity Los Angeles Hematology Oncology Medical Group | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1222307189 |
| Principal investigator 1 | Genentech, Inc. | $26,064.00 | 01/22/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211621329 |
| Principal investigator 1 | Genentech, Inc. | $830.00 | 01/17/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211621345 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,500.20 | 01/15/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | No dispute reported | 06/30/2026 | 1185544465 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 01/14/2025 | Non-covered Recipient Entity ?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325330 |
| Principal investigator 1 | Incyte Corporation | $118.76 | 01/14/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240547958 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,676.88 | 01/03/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185544457 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $140,529.85 | 01/03/2025 | Non-covered Recipient Entity LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185544469 |